NuCana plc is a pioneering brand in the field of oncology. The name NuCana reflects their mission to innovate and deliver groundbreaking medicines for treating cancer. Their products are known as ProTides, which are completely new and innovative cancer treatments.

NuCana has a rich history of achievements and milestones. They began operations in 2008, and since then, they have made significant progress. In 2011, they received Series A financing to accelerate the clinical development of ProTides.

In subsequent years, they entered various clinical studies for different types of cancer, such as solid tumors, ovarian cancer, pancreatic cancer, and biliary tract cancer. The brand has an experienced and dedicated executive team, led by CEO Hugh Griffith. With over 30 years of experience in the biopharmaceutical industry, Hugh is passionate about driving the development of NuCana's important anti-cancer medicines.

The team also includes professionals like Don Munoz, the Chief Financial Officer, Jeffrey Bloss, the Chief Medical Officer, and David Harrison, the Head of Translational Medicine. NuCana's commitment to revolutionize cancer treatment has earned them recognition and awards, including the Outstanding Contribution Award and multiple Investment of the Year awards from Scottish Life Sciences. Overall, NuCana is a brand that is revolutionizing the fight against cancer through its innovative ProTides and a dedicated team of experts